XML 46 R30.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revisions of Previously-Issued Financial Statements (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2018
Accounting Changes And Error Corrections [Abstract] |
Summary of Effect of Corrections on Previously Reported Consolidated Financial Statements | The following tables presents the revised results for each previously reported period, the adjustments made to each period and the previously reported amounts to summarize the effect of the corrections on the previously reported consolidated financial statements for the periods presented.
|  |  | Year ended June 30, |
|  |  | 2017 |
|  |  | (As Reported) |  | (Adjustment) |  | (Restated) |
ASSETS |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  | $ | 102.4 |  | $ | - |  | $ | 102.4 |
Marketable investment securities |  |  |  | 48.3 |  |  | - |  |  | 48.3 |
Prepaid expenses |  |  |  | 12.7 |  |  | - |  |  | 12.7 |
Inventory |  |  |  | 42.2 |  |  | - |  |  | 42.2 |
Trade accounts receivable, less allowance for doubtful accounts of $7.6 in 2017 |  |  |  | 105.6 |  |  | (15.4 | ) |  | 90.2 |
Prepaid taxes |  |  |  | 0.2 |  |  | - |  |  | 0.2 |
Other receivables |  |  |  | 5.7 |  |  | - |  |  | 5.7 |
Total current assets |  |  |  | 317.1 |  |  | (15.4 | ) |  | 301.7 |
Property, plant and equipment, net |  |  |  | 51.1 |  |  | - |  |  | 51.1 |
Long-term marketable investment securities |  |  |  | 48.5 |  |  | - |  |  | 48.5 |
Intangibles, net |  |  |  | 491.6 |  |  | (0.1 | ) |  | 491.5 |
Goodwill |  |  |  | 316.1 |  |  | - |  |  | 316.1 |
Total assets |  |  | $ | 1,224.4 |  | $ | (15.5 | ) | $ | 1,208.9 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  |  | $ | 22.0 |  | $ | - |  | $ | 22.0 |
Accrued liabilities |  |  |  | 65.6 |  |  | - |  |  | 65.6 |
Short-term contingent consideration |  |  |  | 127.3 |  |  | - |  |  | 127.3 |
Deferred revenue |  |  |  | 2.6 |  |  | - |  |  | 2.6 |
Total current liabilities |  |  |  | 217.5 |  |  | - |  |  | 217.5 |
Unrecognized tax benefits |  |  |  | 25.2 |  |  | - |  |  | 25.2 |
Other long-term liabilities |  |  |  | 7.2 |  |  | - |  |  | 7.2 |
Contingent consideration |  |  |  | 13.2 |  |  | - |  |  | 13.2 |
Long-term debt |  |  |  | 99.1 |  |  | - |  |  | 99.1 |
Long-term deferred taxes |  |  |  | 84.4 |  |  | (5.7 | ) |  | 78.7 |
Total liabilities |  |  |  | 446.6 |  |  | (5.7 | ) |  | 440.9 |
Commitments and contingencies |  |  |  |  |  |  |  |  |  |  |
Stockholders’ equity: |  |  |  |  |  |  |  |  |  |  |
Common stock, 68.4 shares outstanding at June 30, 2017 |  |  |  | 0.7 |  |  | - |  |  | 0.7 |
Additional paid-in capital |  |  |  | 851.4 |  |  | - |  |  | 851.4 |
Accumulated other comprehensive loss |  |  |  | (5.5 | ) |  | - |  |  | (5.5 | )
Accumulated deficit |  |  |  | (68.4 | ) |  | (9.8 | ) |  | (78.2 | )
Total Myriad Genetics, Inc. stockholders' equity |  |  |  | 778.2 |  |  | (9.8 | ) |  | 768.4 |
Non-controlling interest |  |  |  | (0.4 | ) |  | - |  |  | (0.4 | )
Total stockholders' equity |  |  |  | 777.8 |  |  | (9.8 | ) |  | 768.0 |
Total liabilities and stockholders’ equity |  |  | $ | 1,224.4 |  | $ | (15.5 | ) | $ | 1,208.9 |
In millions, except per share amounts |  | Year Ended June 30, |
|  | 2017 |
|  | (As Reported) |  | (Adjustment) |  | (Restated) |
Molecular diagnostic testing |  | $ | 722.1 |  | $ | (1.5 | ) | $ | 720.6 |
Pharmaceutical and clinical services |  |  | 49.3 |  |  | - |  |  | 49.3 |
Total revenue |  |  | 771.4 |  |  | (1.5 | ) |  | 769.9 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 145.2 |  |  | - |  |  | 145.2 |
Cost of pharmaceutical and clinical services |  |  | 26.0 |  |  | - |  |  | 26.0 |
Research and development expense |  |  | 74.4 |  |  | - |  |  | 74.4 |
Change in the fair value of contingent consideration |  |  | (0.8 | ) |  | - |  |  | (0.8 | )
Selling, general, and administrative expense |  |  | 476.4 |  |  | - |  |  | 476.4 |
Total costs and expenses |  |  | 721.2 |  |  | - |  |  | 721.2 |
Operating income |  |  | 50.2 |  |  | (1.5 | ) |  | 48.7 |
Other income (expense): |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 1.2 |  |  | - |  |  | 1.2 |
Interest expense |  |  | (6.0 | ) |  | - |  |  | (6.0 | )
Other |  |  | (2.5 | ) |  | (0.5 | ) |  | (3.0 | )
Total other income (expense): |  |  | (7.3 | ) |  | (0.5 | ) |  | (7.8 | )
Income before income tax |  |  | 42.9 |  |  | (2.0 | ) |  | 40.9 |
Income tax provision |  |  | 21.3 |  |  | (0.7 | ) |  | 20.6 |
Net income |  |  | 21.6 |  |  | (1.3 | ) |  | 20.3 |
Net loss attributable to non-controlling interest |  |  | (0.2 | ) |  | - |  |  | (0.2 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 21.8 |  | $ | (1.3 | ) | $ | 20.5 |
Earnings per share: |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.32 |  | $ | (0.02 | ) | $ | 0.30 |
Diluted |  | $ | 0.32 |  | $ | (0.02 | ) | $ | 0.30 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |
Basic |  |  | 68.3 |  |  | 68.3 |  |  | 68.3 |
Diluted |  |  | 68.8 |  |  | 68.8 |  |  | 68.8 |
In millions, except per share amounts |  | Year Ended June 30, |
|  | 2016 |
|  | (As Reported) |  | (Adjustment) |  | (Restated) |
Molecular diagnostic testing |  | $ | 705.7 |  | $ | (13.3 | ) | $ | 692.4 |
Pharmaceutical and clinical services |  |  | 48.1 |  |  | - |  |  | 48.1 |
Total revenue |  |  | 753.8 |  |  | (13.3 | ) |  | 740.5 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 132.8 |  |  | - |  |  | 132.8 |
Cost of pharmaceutical and clinical services |  |  | 24.5 |  |  | - |  |  | 24.5 |
Research and development expense |  |  | 70.6 |  |  | - |  |  | 70.6 |
Change in the fair value of contingent consideration |  |  | - |  |  | - |  |  | - |
Selling, general, and administrative expense |  |  | 359.1 |  |  | 0.1 |  |  | 359.2 |
Total costs and expenses |  |  | 587.0 |  |  | 0.1 |  |  | 587.1 |
Operating income |  |  | 166.8 |  |  | (13.4 | ) |  | 153.4 |
Other income (expense): |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.9 |  |  | - |  |  | 0.9 |
Interest expense |  |  | (0.3 | ) |  | - |  |  | (0.3 | )
Other |  |  | 1.5 |  |  | 0.5 |  |  | 2.0 |
Total other income (expense): |  |  | 2.1 |  |  | 0.5 |  |  | 2.6 |
Income before income tax |  |  | 168.9 |  |  | (12.9 | ) |  | 156.0 |
Income tax provision |  |  | 43.6 |  |  | (4.8 | ) |  | 38.8 |
Net income |  |  | 125.3 |  |  | (8.1 | ) |  | 117.2 |
Net loss attributable to non-controlling interest |  |  | - |  |  | - |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 125.3 |  | $ | (8.1 | ) | $ | 117.2 |
Earnings per share: |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 1.79 |  | $ | (0.12 | ) | $ | 1.67 |
Diluted |  | $ | 1.71 |  | $ | (0.11 | ) | $ | 1.60 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |
Basic |  |  | 70.0 |  |  | 70.0 |  |  | 70.0 |
Diluted |  |  | 73.4 |  |  | 73.4 |  |  | 73.4 |
In millions, except per share amounts |  | Year Ended June 30, |
|  | 2015 |
|  | (As Reported) |  | (Adjustment) |  | (Restated) |
Molecular diagnostic testing |  | $ | 695.5 |  | $ | (0.6 | ) | $ | 694.9 |
Pharmaceutical and clinical services |  |  | 27.6 |  |  | - |  |  | 27.6 |
Total revenue |  |  | 723.1 |  |  | (0.6 | ) |  | 722.5 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 132.8 |  |  | - |  |  | 132.8 |
Cost of pharmaceutical and clinical services |  |  | 14.6 |  |  | - |  |  | 14.6 |
Research and development expense |  |  | 75.5 |  |  | - |  |  | 75.5 |
Change in the fair value of contingent consideration |  |  | - |  |  | - |  |  | - |
Selling, general, and administrative expense |  |  | 366.0 |  |  | - |  |  | 366.0 |
Total costs and expenses |  |  | 588.9 |  |  | - |  |  | 588.9 |
Operating income |  |  | 134.2 |  |  | (0.6 | ) |  | 133.6 |
Other income (expense): |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.4 |  |  | - |  |  | 0.4 |
Interest expense |  |  | (0.2 | ) |  | - |  |  | (0.2 | )
Other |  |  | 0.5 |  |  | - |  |  | 0.5 |
Total other income (expense): |  |  | 0.7 |  |  | - |  |  | 0.7 |
Income before income tax |  |  | 134.9 |  |  | (0.6 | ) |  | 134.3 |
Income tax provision |  |  | 54.7 |  |  | (0.2 | ) |  | 54.5 |
Net income |  |  | 80.2 |  |  | (0.4 | ) |  | 79.8 |
Net loss attributable to non-controlling interest |  |  | - |  |  | - |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 80.2 |  | $ | (0.4 | ) | $ | 79.8 |
Earnings per share: |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 1.12 |  | $ | (0.01 | ) | $ | 1.12 |
Diluted |  | $ | 1.08 |  | $ | (0.01 | ) | $ | 1.07 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |
Basic |  |  | 71.3 |  |  | 71.3 |  |  | 71.3 |
Diluted |  |  | 74.5 |  |  | 74.5 |  |  | 74.5 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2018 |  |  | 2017 |  |  | 2017 |
Consolidated Statement of Operations Data: |  | (Restated) |  |  | (Restated) |  |  | (Restated) |
Molecular diagnostic testing |  | $ | 177.3 |  |  | $ | 177.9 |  |  | $ | 176.5 |
Pharmaceutical and clinical services |  |  | 13.8 |  |  |  | 14.8 |  |  |  | 11.4 |
Total Revenue |  |  | 191.1 |  |  |  | 192.7 |  |  |  | 187.9 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 36.8 |  |  |  | 37.7 |  |  |  | 36.2 |
Cost of pharmaceutical and clinical services |  |  | 7.3 |  |  |  | 6.7 |  |  |  | 6.8 |
Research and development expense |  |  | 18.5 |  |  |  | 16.8 |  |  |  | 17.8 |
Change in the fair value of contingent consideration |  |  | (1.2 | ) |  |  | 13.0 |  |  |  | (73.2 | )
Selling, general and administrative expense |  |  | 115.1 |  |  |  | 115.4 |  |  |  | 115.2 |
Total costs and expenses |  |  | 176.5 |  |  |  | 189.6 |  |  |  | 102.8 |
Operating income |  |  | 14.6 |  |  |  | 3.1 |  |  |  | 85.1 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.5 |  |  |  | 0.4 |  |  |  | 0.4 |
Interest expense |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.9 | )
Other |  |  | (0.5 | ) |  |  | (0.4 | ) |  |  | (0.3 | )
Total other income (expense) |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.8 | )
Income before income taxes |  |  | 14.1 |  |  |  | 2.4 |  |  |  | 84.3 |
Income tax provision |  |  | 4.5 |  |  |  | (26.3 | ) |  |  | 4.8 |
Net income |  |  | 9.6 |  |  |  | 28.7 |  |  |  | 79.5 |
Net loss attributable to non-controlling interest |  |  | (0.1 | ) |  |  | - |  |  |  | (0.1 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 9.7 |  |  | $ | 28.7 |  |  | $ | 79.6 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.14 |  |  | $ | 0.41 |  |  | $ | 1.16 |
Diluted |  | $ | 0.13 |  |  | $ | 0.40 |  |  | $ | 1.13 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 69.8 |  |  |  | 69.3 |  |  |  | 68.6 |
Diluted |  |  | 72.4 |  |  |  | 71.9 |  |  |  | 70.4 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2018 |  |  | 2017 |  |  | 2017 |
Consolidated Statement of Operations Data: |  | (adjustments) |  |  | (adjustments) |  |  | (adjustments) |
Molecular diagnostic testing |  | $ | (2.4 | ) |  | $ | (1.3 | ) |  | $ | (2.3 | )
Pharmaceutical and clinical services |  |  | - |  |  |  | - |  |  |  | - |
Total Revenue |  |  | (2.4 | ) |  |  | (1.3 | ) |  |  | (2.3 | )
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | - |  |  |  | - |  |  |  | - |
Cost of pharmaceutical and clinical services |  |  | - |  |  |  | - |  |  |  | - |
Research and development expense |  |  | - |  |  |  | - |  |  |  | - |
Change in the fair value of contingent consideration |  |  | - |  |  |  | - |  |  |  | - |
Selling, general and administrative expense |  |  | - |  |  |  | - |  |  |  | - |
Total costs and expenses |  |  | - |  |  |  | - |  |  |  | - |
Operating income |  |  | (2.4 | ) |  |  | (1.3 | ) |  |  | (2.3 | )
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | - |  |  |  | - |  |  |  | - |
Interest expense |  |  | - |  |  |  | - |  |  |  | - |
Other |  |  | - |  |  |  | - |  |  |  | - |
Total other income (expense) |  |  | - |  |  |  | - |  |  |  | - |
Income before income taxes |  |  | (2.4 | ) |  |  | (1.3 | ) |  |  | (2.3 | )
Income tax provision |  |  | (0.7 | ) |  |  | 2.1 |  |  |  | (0.8 | )
Net income |  |  | (1.7 | ) |  |  | (3.4 | ) |  |  | (1.5 | )
Net loss attributable to non-controlling interest |  |  | - |  |  |  | - |  |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | (1.7 | ) |  | $ | (3.4 | ) |  | $ | (1.5 | )
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.02 | ) |  | $ | (0.05 | ) |  | $ | (0.02 | )
Diluted |  | $ | (0.02 | ) |  | $ | (0.05 | ) |  | $ | (0.02 | )
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 69.8 |  |  |  | 69.3 |  |  |  | 68.6 |
Diluted |  |  | 72.4 |  |  |  | 71.9 |  |  |  | 70.4 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2018 |  |  | 2017 |  |  | 2017 |
Consolidated Statement of Operations Data: |  | (As Reported) |  |  | (As Reported) |  |  | (As Reported) |
Molecular diagnostic testing |  | $ | 179.7 |  |  | $ | 179.2 |  |  | $ | 178.8 |
Pharmaceutical and clinical services |  |  | 13.8 |  |  |  | 14.8 |  |  |  | 11.4 |
Total Revenue |  |  | 193.5 |  |  |  | 194.0 |  |  |  | 190.2 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 36.8 |  |  |  | 37.7 |  |  |  | 36.2 |
Cost of pharmaceutical and clinical services |  |  | 7.3 |  |  |  | 6.7 |  |  |  | 6.8 |
Research and development expense |  |  | 18.5 |  |  |  | 16.8 |  |  |  | 17.8 |
Change in the fair value of contingent consideration |  |  | (1.2 | ) |  |  | 13.0 |  |  |  | (73.2 | )
Selling, general and administrative expense |  |  | 115.1 |  |  |  | 115.4 |  |  |  | 115.2 |
Total costs and expenses |  |  | 176.5 |  |  |  | 189.6 |  |  |  | 102.8 |
Operating income |  |  | 17.0 |  |  |  | 4.4 |  |  |  | 87.4 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.5 |  |  |  | 0.4 |  |  |  | 0.4 |
Interest expense |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.9 | )
Other |  |  | (0.5 | ) |  |  | (0.4 | ) |  |  | (0.3 | )
Total other income (expense) |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.8 | )
Income before income taxes |  |  | 16.5 |  |  |  | 3.7 |  |  |  | 86.6 |
Income tax provision |  |  | 5.2 |  |  |  | (28.4 | ) |  |  | 5.6 |
Net income |  |  | 11.3 |  |  |  | 32.1 |  |  |  | 81.0 |
Net loss attributable to non-controlling interest |  |  | (0.1 | ) |  |  | - |  |  |  | (0.1 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 11.4 |  |  | $ | 32.1 |  |  | $ | 81.1 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.16 |  |  | $ | 0.46 |  |  | $ | 1.18 |
Diluted |  | $ | 0.16 |  |  | $ | 0.45 |  |  | $ | 1.15 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 69.8 |  |  |  | 69.3 |  |  |  | 68.6 |
Diluted |  |  | 72.4 |  |  |  | 71.9 |  |  |  | 70.4 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2017 |  |  | 2017 |  |  | 2016 |  |  | 2016 |
Consolidated Statement of Operations Data: |  | (Restated) |  |  | (Restated) |  |  | (Restated) |  |  | (Restated) |
Molecular diagnostic testing |  | $ | 187.0 |  |  | $ | 183.0 |  |  | $ | 184.1 |  |  | $ | 166.5 |
Pharmaceutical and clinical services |  |  | 12.6 |  |  |  | 11.7 |  |  |  | 12.6 |  |  |  | 12.4 |
Total Revenue |  |  | 199.6 |  |  |  | 194.7 |  |  |  | 196.7 |  |  |  | 178.9 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 35.6 |  |  |  | 37.9 |  |  |  | 37.4 |  |  |  | 34.3 |
Cost of pharmaceutical and clinical services |  |  | 6.9 |  |  |  | 6.4 |  |  |  | 7.0 |  |  |  | 5.7 |
Research and development expense |  |  | 18.8 |  |  |  | 17.6 |  |  |  | 18.6 |  |  |  | 19.4 |
Change in the fair value of contingent consideration |  |  | (2.7 | ) |  |  | 5.2 |  |  |  | (3.8 | ) |  |  | 0.5 |
Selling, general and administrative expense |  |  | 122.1 |  |  |  | 122.1 |  |  |  | 120.3 |  |  |  | 111.9 |
Total costs and expenses |  |  | 180.7 |  |  |  | 189.2 |  |  |  | 179.5 |  |  |  | 171.8 |
Operating income |  |  | 18.9 |  |  |  | 5.5 |  |  |  | 17.2 |  |  |  | 7.1 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |
Interest expense |  |  | (1.2 | ) |  |  | (1.5 | ) |  |  | (2.6 | ) |  |  | (0.7 | )
Other |  |  | (0.1 | ) |  |  | 1.5 |  |  |  | (2.6 | ) |  |  | (1.8 | )
Total other income (expense) |  |  | (1.0 | ) |  |  | 0.3 |  |  |  | (4.9 | ) |  |  | (2.2 | )
Income before income taxes |  |  | 17.9 |  |  |  | 5.8 |  |  |  | 12.3 |  |  |  | 4.9 |
Income tax provision |  |  | 5.8 |  |  |  | 3.0 |  |  |  | 6.2 |  |  |  | 5.6 |
Net income |  |  | 12.1 |  |  |  | 2.8 |  |  |  | 6.1 |  |  |  | (0.7 | )
Net loss attributable to non-controlling interest |  |  | (0.2 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 12.3 |  |  | $ | 2.8 |  |  | $ | 6.1 |  |  | $ | (0.7 | )
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.18 |  |  | $ | 0.04 |  |  | $ | 0.09 |  |  | $ | (0.01 | )
Diluted |  | $ | 0.18 |  |  | $ | 0.04 |  |  | $ | 0.09 |  |  | $ | (0.01 | )
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 68.2 |  |  |  | 68.1 |  |  |  | 68.2 |  |  |  | 68.8 |
Diluted |  |  | 68.9 |  |  |  | 68.3 |  |  |  | 68.3 |  |  |  | 68.8 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2017 |  |  | 2017 |  |  | 2016 |  |  | 2016 |
Consolidated Statement of Operations Data: |  | (adjustments) |  |  | (adjustments) |  |  | (adjustments) |  |  | (adjustments) |
Molecular diagnostic testing |  | $ | (0.9 | ) |  | $ | (2.2 | ) |  | $ | 0.2 |  |  | $ | 1.4 |
Pharmaceutical and clinical services |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Total Revenue |  |  | (0.9 | ) |  |  | (2.2 | ) |  |  | 0.2 |  |  |  | 1.4 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Cost of pharmaceutical and clinical services |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Research and development expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Change in the fair value of contingent consideration |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Selling, general and administrative expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Total costs and expenses |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Operating income |  |  | (0.9 | ) |  |  | (2.2 | ) |  |  | 0.2 |  |  |  | 1.4 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Interest expense |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Other |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (0.5 | )
Total other income (expense) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (0.5 | )
Income before income taxes |  |  | (0.9 | ) |  |  | (2.2 | ) |  |  | 0.2 |  |  |  | 0.9 |
Income tax provision |  |  | (0.3 | ) |  |  | (0.8 | ) |  |  | - |  |  |  | 0.4 |
Net income |  |  | (0.6 | ) |  |  | (1.4 | ) |  |  | 0.2 |  |  |  | 0.5 |
Net loss attributable to non-controlling interest |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | (0.6 | ) |  | $ | (1.4 | ) |  | $ | 0.2 |  |  | $ | 0.5 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.01 | ) |  | $ | (0.02 | ) |  | $ | 0.00 |  |  | $ | 0.01 |
Diluted |  | $ | (0.01 | ) |  | $ | (0.02 | ) |  | $ | 0.00 |  |  | $ | 0.01 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 68.2 |  |  |  | 68.1 |  |  |  | 68.2 |  |  |  | 68.8 |
Diluted |  |  | 68.9 |  |  |  | 68.3 |  |  |  | 68.3 |  |  |  | 68.8 |
In millions, except per share amounts |  | Quarters Ended |
Unaudited |  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
|  | 2017 |  |  | 2017 |  |  | 2016 |  |  | 2016 |
Consolidated Statement of Operations Data: |  | (As Reported) |  |  | (As Reported) |  |  | (As Reported) |  |  | (As Reported) |
Molecular diagnostic testing |  | $ | 187.9 |  |  | $ | 185.2 |  |  | $ | 183.9 |  |  | $ | 165.1 |
Pharmaceutical and clinical services |  |  | 12.6 |  |  |  | 11.7 |  |  |  | 12.6 |  |  |  | 12.4 |
Total Revenue |  |  | 200.5 |  |  |  | 196.9 |  |  |  | 196.5 |  |  |  | 177.5 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 35.6 |  |  |  | 37.9 |  |  |  | 37.4 |  |  |  | 34.3 |
Cost of pharmaceutical and clinical services |  |  | 6.9 |  |  |  | 6.4 |  |  |  | 7.0 |  |  |  | 5.7 |
Research and development expense |  |  | 18.8 |  |  |  | 17.6 |  |  |  | 18.6 |  |  |  | 19.4 |
Change in the fair value of contingent consideration |  |  | (2.7 | ) |  |  | 5.2 |  |  |  | (3.8 | ) |  |  | 0.5 |
Selling, general and administrative expense |  |  | 122.1 |  |  |  | 122.1 |  |  |  | 120.3 |  |  |  | 111.9 |
Total costs and expenses |  |  | 180.7 |  |  |  | 189.2 |  |  |  | 179.5 |  |  |  | 171.8 |
Operating income |  |  | 19.8 |  |  |  | 7.7 |  |  |  | 17.0 |  |  |  | 5.7 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |  |  |  | 0.3 |
Interest expense |  |  | (1.2 | ) |  |  | (1.5 | ) |  |  | (2.6 | ) |  |  | (0.7 | )
Other |  |  | (0.1 | ) |  |  | 1.5 |  |  |  | (2.6 | ) |  |  | (1.3 | )
Total other income (expense) |  |  | (1.0 | ) |  |  | 0.3 |  |  |  | (4.9 | ) |  |  | (1.7 | )
Income before income taxes |  |  | 18.8 |  |  |  | 8.0 |  |  |  | 12.1 |  |  |  | 4.0 |
Income tax provision |  |  | 6.1 |  |  |  | 3.8 |  |  |  | 6.2 |  |  |  | 5.2 |
Net income |  |  | 12.7 |  |  |  | 4.2 |  |  |  | 5.9 |  |  |  | (1.2 | )
Net loss attributable to non-controlling interest |  |  | (0.2 | ) |  |  | - |  |  |  | - |  |  |  | - |
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 12.9 |  |  | $ | 4.2 |  |  | $ | 5.9 |  |  | $ | (1.2 | )
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.19 |  |  | $ | 0.06 |  |  | $ | 0.09 |  |  | $ | (0.02 | )
Diluted |  | $ | 0.19 |  |  | $ | 0.06 |  |  | $ | 0.09 |  |  | $ | (0.02 | )
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 68.2 |  |  |  | 68.1 |  |  |  | 68.2 |  |  |  | 68.8 |
Diluted |  |  | 68.9 |  |  |  | 68.3 |  |  |  | 68.3 |  |  |  | 68.8 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingChangesAndErrorCorrectionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration